Grant: Discovery Grants Program - Individual
York University
$29,000.00
Development and Application of Mass Spectrometry Imaging to Tissue Biomarker Discovery
EF 2022-23
Résumé
In this research program, we propose to develop and apply mass spectrometric (MS) tools in the discovery and validation of cancer biomarkers. We will initiate the project using oral cavity cancer samples since it has high clinical relevance (30 percent of the head and neck region cancers occur in the oral cavity). Our initial studies are designed to chemically map different types of compounds, mostly lipids, within tissue samples. We will be able to highlight the differences in lipid profiles and their relative intensities between normal and cancer tissue by the application of specific statistics tools. We will identify the most characterising molecules and develop multivariate models to identify cancer tissues in patient samples. After identification of potential biomarkers, we will validate the findings with metabolomic tools and develop targeted MS technologies to enhance the detection of biomarkers present in low abundance in complex biological tissue samples. The proposed research will develop diagnostic technologies that are more sensitive and accurate than those currently in use. These technologies will be used in the early detection of cancers and in prognostic studies to identify patients with high potential to cancer recurrence or drug response studies to predict patient response to specific treatments. Since early disease detection and intervention are critical to reducing health care costs and improving patient outcomes, the development of clinical mass spectrometry will have significant economic impact on the healthcare system.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2018-05868
Name nom
Ifa, Demian
Department département
Chemistry - Chemistry
Organization id
38
Institution établissement
York University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2018
Award amount
29000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3500
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Analytical chemistry
Research subject fr
Chimie analytique
Installment
inst:5
Partie
1
Nb partie
6
Application title
Development and Application of Mass Spectrometry Imaging to Tissue Biomarker Discovery
Application summary
In this research program, we propose to develop and apply mass spectrometric (MS) tools in the discovery and validation of cancer biomarkers. We will initiate the project using oral cavity cancer samples since it has high clinical relevance (30 percent of the head and neck region cancers occur in the oral cavity). Our initial studies are designed to chemically map different types of compounds, mostly lipids, within tissue samples. We will be able to highlight the differences in lipid profiles and their relative intensities between normal and cancer tissue by the application of specific statistics tools. We will identify the most characterising molecules and develop multivariate models to identify cancer tissues in patient samples. After identification of potential biomarkers, we will validate the findings with metabolomic tools and develop targeted MS technologies to enhance the detection of biomarkers present in low abundance in complex biological tissue samples. The proposed research will develop diagnostic technologies that are more sensitive and accurate than those currently in use. These technologies will be used in the early detection of cancers and in prognostic studies to identify patients with high potential to cancer recurrence or drug response studies to predict patient response to specific treatments. Since early disease detection and intervention are critical to reducing health care costs and improving patient outcomes, the development of clinical mass spectrometry will have significant economic impact on the healthcare system.